Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP
Amlogenyx Inc., a subsidiary of Ultragenyx Pharmaceutical (NASDAQ: RARE), has successfully closed a $14 million seed funding round led by GordonMD® Global Investments LP. The company is developing novel gene therapies for Alzheimer's disease and other amyloid diseases. Amlogenyx's first product candidate is a protease developed in collaboration with St. Jude Children's Research Hospital, which has shown promising results in breaking down Aβ42, a protein believed to be responsible for Alzheimer's effects.
Dr. Craig Gordon, Founder and CIO of GordonMD®, expressed excitement about the collaboration and the potential of Amlogenyx's Alzheimer's disease therapeutic. The funding round also included participation from Ultragenyx and associated investors, demonstrating strong support for Amlogenyx's innovative approach to treating amyloid diseases.
Amlogenyx Inc., una sussidiaria di Ultragenyx Pharmaceutical (NASDAQ: RARE), ha chiuso con successo un round di finanziamento seed da 14 milioni di dollari guidato da GordonMD® Global Investments LP. L'azienda sta sviluppando nuove terapie geniche per la malattia di Alzheimer e altre malattie amiloidi. Il primo candidato prodotto di Amlogenyx è una proteasi sviluppata in collaborazione con il St. Jude Children's Research Hospital, che ha mostrato risultati promettenti nella degradazione dell'Aβ42, una proteina ritenuta responsabile degli effetti dell'Alzheimer.
Il Dr. Craig Gordon, fondatore e CIO di GordonMD®, ha espresso entusiasmo per la collaborazione e il potenziale terapeutico di Amlogenyx contro la malattia di Alzheimer. Il round di finanziamento ha visto anche la partecipazione di Ultragenyx e investitori associati, dimostrando un forte sostegno per l'approccio innovativo di Amlogenyx nel trattamento delle malattie amiloidi.
Amlogenyx Inc., una subsidiaria de Ultragenyx Pharmaceutical (NASDAQ: RARE), ha cerrado con éxito una liderada por GordonMD® Global Investments LP. La empresa está desarrollando nuevas terapias génicas para la enfermedad de Alzheimer y otras enfermedades amiloides. El primer candidato a producto de Amlogenyx es una proteasa desarrollada en colaboración con el St. Jude Children's Research Hospital, que ha mostrado resultados prometedores en la descomposición de Aβ42, una proteína que se cree es responsable de los efectos del Alzheimer.
El Dr. Craig Gordon, fundador y CIO de GordonMD®, expresó su entusiasmo por la colaboración y el potencial terapéutico de Amlogenyx para la enfermedad de Alzheimer. La ronda de financiamiento también incluyó la participación de Ultragenyx y de inversores asociados, demostrando un fuerte apoyo al enfoque innovador de Amlogenyx para tratar las enfermedades amiloides.
Amlogenyx Inc.는 Ultragenyx Pharmaceutical (NASDAQ: RARE)의 자회사로, GordonMD® Global Investments LP가 주도한 1400만 달러 규모의 시드 펀딩 라운드를 성공적으로 마감했습니다. 이 회사는 알츠하이머병 및 기타 아밀로이드 질환을 위한 새로운 유전자 치료제를 개발하고 있습니다. Amlogenyx의 첫 번째 제품 후보는 St. Jude Children's Research Hospital과의 협력으로 개발된 효소로, 알츠하이머의 영향을 주는 것으로 여겨지는 Aβ42 단백질을 분해하는 데 유망한 결과를 보여주고 있습니다.
GordonMD®의 창립자이자 CIO인 Craig Gordon 박사는 협력과 Amlogenyx의 알츠하이머병 치료의 잠재력에 대한 기대를 표명했습니다. 이번 펀딩 라운드에는 Ultragenyx와 관련 투자자들도 참여하여 Amlogenyx의 혁신적인 아밀로이드 질환 치료 접근 방식에 대한 강한 지지를 보여주었습니다.
Amlogenyx Inc., une filiale d'Ultragenyx Pharmaceutical (NASDAQ: RARE), a réussi à clôturer un tour de financement initial de 14 millions de dollars dirigé par GordonMD® Global Investments LP. L'entreprise développe de nouvelles thérapies géniques pour la maladie d'Alzheimer et d'autres maladies amyloïdes. Le premier candidat produit d'Amlogenyx est une protéase développée en collaboration avec l'hôpital de recherche pour enfants St. Jude, qui a montré des résultats prometteurs dans la dégradation de l'Aβ42, une protéine que l'on pense responsable des effets de la maladie d'Alzheimer.
Le Dr Craig Gordon, fondateur et CIO de GordonMD®, a exprimé son enthousiasme pour la collaboration et le potentiel thérapeutique d'Amlogenyx dans le traitement de la maladie d'Alzheimer. Le tour de financement a également inclus la participation d'Ultragenyx et d'investisseurs associés, démontrant un fort soutien pour l'approche innovante d'Amlogenyx dans le traitement des maladies amyloïdes.
Amlogenyx Inc., eine Tochtergesellschaft von Ultragenyx Pharmaceutical (NASDAQ: RARE), hat erfolgreich eine Seed-Finanzierungsrunde in Höhe von 14 Millionen US-Dollar abgeschlossen, die von GordonMD® Global Investments LP geleitet wurde. Das Unternehmen entwickelt neuartige Gentherapien für Alzheimer-Krankheit und andere Amyloid-Erkrankungen. Der erste Produktkandidat von Amlogenyx ist eine Protease, die in Zusammenarbeit mit dem St. Jude Children's Research Hospital entwickelt wurde und vielversprechende Ergebnisse beim Abbau von Aβ42 gezeigt hat, einem Protein, das als verantwortlich für die Auswirkungen von Alzheimer gilt.
Dr. Craig Gordon, Gründer und CIO von GordonMD®, äußerte Begeisterung über die Zusammenarbeit und das Potenzial von Amlogenyx' Therapieansatz gegen Alzheimer. An der Finanzierungsrunde nahmen auch Ultragenyx und assoziierte Investoren teil, was die starke Unterstützung für den innovativen Ansatz von Amlogenyx zur Behandlung von Amyloid-Erkrankungen zeigt.
- Successful completion of $14 million seed funding round
- Development of a promising Alzheimer's disease therapeutic
- Collaboration with St. Jude Children's Research Hospital
- Potential breakthrough in treating amyloid diseases
- None.
The $14 million seed funding for Amlogenyx, a subsidiary of Ultragenyx Pharmaceutical (NASDAQ: RARE), represents a significant milestone in the company's development of gene therapies for Alzheimer's and other amyloid diseases. This investment, led by GordonMD® Global Investments LP, signals strong investor confidence in Amlogenyx's innovative approach.
From a financial perspective, this funding provides Amlogenyx with important capital to advance its research and development efforts. For Ultragenyx, this investment could potentially enhance its market position and diversify its pipeline. The involvement of a notable investor like GordonMD® adds credibility to the project and may attract further investment in future rounds.
However, it's important to note that while
The market for Alzheimer's treatments is vast, with an estimated 6.2 million Americans living with the disease. A successful therapy could potentially generate billions in revenue. However, the field is also notorious for high failure rates in clinical trials. Investors should balance the enormous potential with the inherent risks in biotech investments, especially those targeting Alzheimer's disease.
The seed funding for Amlogenyx's novel gene therapy approach to Alzheimer's disease is scientifically intriguing. Their focus on a protease that can break down Aβ42, a protein widely believed to be a key player in Alzheimer's pathology, represents a promising avenue of research.
What's particularly noteworthy is the collaboration with Dr. Sandra D'Azzo at St. Jude Children's Research Hospital. This partnership brings together expertise from a renowned research institution and a biotech company, potentially accelerating the translation of basic science into clinical applications.
The enzyme's ability to "break up and degrade efficiently Aβ42" is a significant finding. Many previous Alzheimer's treatments have focused on preventing Aβ42 formation or clearing it from the brain, but an enzyme that can actively degrade it presents a novel therapeutic strategy. If successful, this approach could not only treat but potentially reverse some of the protein accumulation associated with Alzheimer's.
However, it's important to remember that many promising Alzheimer's treatments have failed in later-stage clinical trials. The complexity of the disease, involving multiple pathological processes beyond just amyloid accumulation, means that even if this therapy effectively clears Aβ42, it may not necessarily translate to clinical improvement. Rigorous clinical trials will be necessary to prove efficacy and safety.
Investors should also note that this technology's potential extends beyond Alzheimer's to "other amyloid diseases," which could include conditions like light chain amyloidosis or transthyretin amyloidosis. This broader application could potentially increase the therapy's market potential if proven effective.
“I am pleased to collaborate with Amlogenyx; its promising Alzheimer’s disease therapeutic has yielded exciting results in pursuing a therapy that has the potential to change the outlook for this disease,” said Dr. Craig Gordon, Founder and Chief Investment Officer of GordonMD®.
“Amlogenyx’s first product candidate is a protease that we developed alongside Sandra D’Azzo Ph.D. at St. Jude Children’s Research Hospital in Memphis,” said Emil Kakkis, M.D., Ph.D., CEO of Ultragenyx. “The study found that the enzyme can break up and degrade efficiently Aβ42, the protein many consider responsible for Alzheimer’s debilitating effects.”
The seed round was led by GordonMD® and associated investors, as well as Ultragenyx.
About GordonMD® Global Investments
GordonMD® Global Investments LP was founded in 2021 by Craig Gordon, MD, a licensed physician with more than 13 years of buy-side experience managing global biopharmaceutical portfolios. The firm focuses on identifying differentiated investment opportunities in biopharmaceutical companies primarily located in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240802647087/en/
Media:
Jim Gold, Lumentus
jgold@lumentus.com 347-968-2912
Source: GordonMD Global Investments LP
FAQ
What is the amount of seed funding raised by Amlogenyx Inc.?
Who led the seed funding round for Amlogenyx Inc.?
What is Amlogenyx Inc. developing?
What is the stock symbol for Ultragenyx Pharmaceutical, Amlogenyx's parent company?
What is the first product candidate of Amlogenyx Inc.?
